Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| MeiraGTx Holdings plc | AAV2-hAQP1 - (AQUAx2) | Xerostomia | Phase 2 | Data Released | Intracanalicular | N/A |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) - (KEYNOTE-B15/EV-304) | Muscle-invasive bladder cancer (MIBC) | PDUFA | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | WINREVAIR (sotatercept-csrk) - (HYPERION) | Pulmonary arterial hypertension (PAH, WHO* Group 1) | PDUFA | Data Released | Subcutaneous | Cardiology |
| Merck & Company Inc. | Doravirine/Islatravir (DOR/ISL) - (MK-8591A-052) | HIV-1 Infection | PDUFA | Data Released | Oral | Anti-HIV |
| Merck & Company Inc. | ENGOT-ov65 - (KEYNOTE-B96) | Platinum-Resistant Recurrent Ovarian Cancer | PDUFA | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | SB5 (adalimumab-bwwd) - (HUMIRA biosimilar) | Crohn's disease | BLA Filing | Subcutaneous | Gastroenterology | |
| Merck & Company Inc. | PREVYMIS (Letermovir) | CMV infection following an HSCT (200 days) | sNDA Filing | Trial Completed | Oral intravenous | Antiviral |
| Merck & Company Inc. | Rezatapopt (PC14586) - (PYNNACLE) | Solid tumors | NDA Filing | Ongoing | oral | Oncology |
